Observational studyCritical care (London, England)2026
SvO₂ response to red blood cell transfusion in cardiovascular surgical icu patients: a retrospective observational study.
Observational study in Critical care (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRed blood cell (RBC) transfusion decisions after cardiovascular surgery require integration of hemoglobin (Hb), hemodynamics, bleeding status, and oxygen supply-demand balance. Mixed venous oxygen saturation (SvO₂) reflects the global relationship between oxygen delivery and oxygen consumption, but an increase in SvO₂ does not necessarily indicate improved tissue oxygenation or clinical benefit. We evaluated acute SvO₂ changes after RBC transfusion in cardiovascular surgical ICU patients.
methodsWe conducted a single-center retrospective cohort study of adult cardiovascular surgical ICU patients who received one RBC-equivalent transfusion with pre-transfusion Hb ≥ 7.5 g/dL and paired pre- and post-transfusion SvO₂ measurements. The primary outcome was an individual-level SvO₂ response, defined a priori as ΔSvO₂ ≥5% points from baseline to approximately 60 min after transfusion initiation. Multivariable regression was used to evaluate predictors selected a priori based on physiologic relevance to oxygen delivery and consumption. Receiver operating characteristic analysis was used to evaluate the discriminative ability of pre-transfusion SvO₂.
results1,352 unique patients met the final inclusion criteria. Mean Hb increased from 9.82 ± 0.92 to 10.24 ± 0.98 g/dL, corresponding to a paired mean difference of 0.42 g/dL (95% CI, 0.38 to 0.46; P < 0.001). Mean SvO₂ changed minimally at the cohort level, from 73.79 ± 9.91% to 73.86 ± 9.37%, corresponding to a paired mean difference of 0.08% points (95% CI, -0.28 to 0.43; P = 0.671). Lower pre-transfusion SvO₂ was associated with a higher probability of an individual-level SvO₂ response. In multivariable logistic regression, pre-transfusion SvO₂ was associated with SvO₂ response (adjusted odds ratio, 0.89 per 1% increase; 95% confidence interval, 0.86-0.91; P < 0.001). Pre-transfusion SvO₂ showed moderate discrimination for SvO₂ response, with an area under the curve of 0.778 (95% confidence interval, 0.740-0.816). The Youden-derived cutoff was 69%, which should be interpreted as an exploratory predictor of acute SvO₂ rise rather than a transfusion trigger.
conclusionsLower pre-transfusion SvO₂ was associated with acute individual-level SvO₂ increase after transfusion, but mean SvO₂ change was minimal. The association did not establish tissue oxygenation or clinical benefit and does not support using SvO₂, including the 69% cutoff, as a transfusion indication or trigger.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.